JG
VKTX icon

Jefferies Group’s Viking Therapeutics VKTX Stock Holding History

Jefferies Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-52,500
Closed -$421K – 2708
2019
Q4 		$421K Hold
52,500
– – ﹤0.01% 1919
2019
Q3 		$361K Hold
52,500
– – ﹤0.01% 2067
2019
Q2 		$436K Hold
52,500
– – ﹤0.01% 1730
2019
Q1 		$522K Buy
52,500
+12,500
+31% +$105K ﹤0.01% 1560
2018
Q4 		$306K Sell
40,000
-10,400
-21% -$124K ﹤0.01% 1650
2018
Q3 		$878K Buy
50,400
+40,000
+385% +$476K 0.01% 1398
2018
Q2 		$99K Buy
+10,400
New +$69.2K ﹤0.01% 2139

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jefferies Group's VKTX Position: Q2 2020 in Review

Jefferies Group sold out of Viking Therapeutics (VKTX) in Q2 2020, closing a stake of 1,627 shares — an estimated $10.8K sold.

Jefferies Group first reported a position in VKTX in Q1 2018 and held it in 8 quarters. The position peaked at $453K in Q2 2019. 138 funds tracked by Wall St. Rank hold VKTX as of Q2 2020.

  • Jefferies Group reported no remaining Viking Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Jefferies Group sold 1,627 Viking Therapeutics shares in Q2 2020, an estimated $10.8K.
  • Jefferies Group first reported a position in Viking Therapeutics in Q1 2018 and held it in 8 quarters.
  • Jefferies Group's Viking Therapeutics position peaked at $453K in Q2 2019.
  • 138 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2020.

Based on Jefferies Group's 13F filing for Q2 2020, filed 14 Aug 2020.